Cepheid:医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Cepheid - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7442
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; molecular diagnostic systems; and reagents and parts. Cepheid distributes its products directly and also through a network of distributors across Americas, Asia, Europe, Africa and the Middle East regions. The company has partnership with small and large biopharmaceutical companies to develop therapies in anti-infective, critical infectious disease and oncology areas. Cepheid is headquartered in Sunnyvale, California, the US.

Cepheid – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cepheid, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cepheid, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cepheid, Medical Equipment, Deal Details 10
Partnerships 10
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 10
SpeeDx Enters into Distribution Agreement with Cepheid 11
Novacyt Enters into Partnership with Cepheid 12
Cepheid, MedImmune and Combacte Enter into Agreement 13
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 14
Sidney Kimmel Cancer Center Enters into Agreement with Cepheid 15
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 16
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 17
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 18
Debt Offering 19
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 19
Acquisition 21
Danaher Acquires Cepheid 21
Cepheid – Key Competitors 23
Cepheid – Key Employees 24
Cepheid – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Government and Public Interest 27
Feb 20, 2018: New IDSA/SHEA Guidelines Highlight Critical Role of PCR Testing in C. difficile Diagnosis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Cepheid, Medical Equipment, Key Facts 2
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cepheid, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cepheid, Deals By Market, 2012 to YTD 2018 8
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 10
SpeeDx Enters into Distribution Agreement with Cepheid 11
Novacyt Enters into Partnership with Cepheid 12
Cepheid, MedImmune and Combacte Enter into Agreement 13
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 14
Sidney Kimmel Cancer Center Enters into Agreement with Cepheid 15
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 16
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 17
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 18
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 19
Danaher Acquires Cepheid 21
Cepheid, Key Competitors 23
Cepheid, Key Employees 24
Cepheid, Subsidiaries 25

List of Figures
Cepheid, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cepheid, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cepheid, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Cepheid:医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sinopharm Group Co Ltd (1099):企業の財務・戦略的SWOT分析
    Sinopharm Group Co Ltd (1099) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Petroleos Mexicanos:石油・ガス:M&Aディール及び事業提携情報
    Summary Petroleos Mexicanos (PEMEX) is a state-owned integrated oil and gas company. It operates across the value chain of oil and gas industry, from exploration and production to processing, logistics and marketing. PEMEX also produces and distributes a wide range of petrochemical products. The com …
  • Cordy Oilfield Services Inc (CKK):石油・ガス:M&Aディール及び事業提携情報
    Summary Cordy Oilfield Services Inc (Cordy) is an oilfield and construction service provider. The company offers construction and environmental services. Its construction services include underground utilities installation and maintenance, pipeline insulation and reclamation, pump jack maintenance, …
  • Clover Corp Ltd (CLV):企業の財務・戦略的SWOT分析
    Summary Clover Corp Ltd (Clover), a subsidiary of Washington H. Soul Pattinson and Company Ltd, is a developer of science-based bioactives. The company offers products such as DHA oils, DHA powders and microencapsulation. It delivers bioactive ingredients through encapsulation. Clover’s refined tuna …
  • Fabric Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Fabric Genomics Inc (Fabric), formerly Omicia Inc is a healthcare solutions provider that offers genome analysis services. The company provides solutions for researchers and clinicians to analyze genomes and disease-causing variants and genes. Its products include opal software and standalon …
  • Gildan Activewear Inc (GIL):企業の財務・戦略的SWOT分析
    Gildan Activewear Inc (GIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Everspin Technologies Inc (MRAM):企業の財務・戦略的SWOT分析
    Everspin Technologies Inc (MRAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Revance Therapeutics Inc (RVNC):製薬・医療:M&Aディール及び事業提携情報
    Summary Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fas …
  • Prime Polymer Co Ltd:企業の戦略的SWOT分析
    Prime Polymer Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • PledPharma AB (PLED):製薬・医療:M&Aディール及び事業提携情報
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Oil States International, Inc.:企業の戦略・SWOT・財務情報
    Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Oil States International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Akers Biosciences Inc (AKER):製薬・医療:M&Aディール及び事業提携情報
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. Its products include BreathScan alcohol detectors, CHUBE, METRO …
  • Kesko Corp (KESKOA):企業の財務・戦略的SWOT分析
    Kesko Corp (KESKOA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Naspers Limited:企業の戦略・SWOT・財務分析
    Naspers Limited - Strategy, SWOT and Corporate Finance Report Summary Naspers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • QDVC Q.S.C:企業の戦略的SWOT分析
    QDVC Q.S.C - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Dover Corporation:企業の戦略・SWOT・財務情報
    Dover Corporation - Strategy, SWOT and Corporate Finance Report Summary Dover Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • APIM Therapeutics AS-製薬・医療分野:企業M&A・提携分析
    Summary APIM Therapeutics AS (APIM) is a drug development company that offers novel anti-cancer therapies. The company offers development of peptide compounds such as mitomycin-c, cisplatin, melphatan, ATX compounds, cytarabine, cisplatin, docetaxel and temozolomide. Its compounds are used in indica …
  • Maruha Nichiro Corporation
    Maruha Nichiro Corporation - Strategy, SWOT and Corporate Finance Report Summary Maruha Nichiro Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Kuehne + Nagel International AG (KNIN):企業の財務・戦略的SWOT分析
    Kuehne + Nagel International AG (KNIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Hyatt Hotels Corporation:企業の戦略・SWOT・財務情報
    Hyatt Hotels Corporation - Strategy, SWOT and Corporate Finance Report Summary Hyatt Hotels Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆